Phathom Pharmaceuticals (PHAT) 25th Annual Needham Virtual Healthcare Conference summary

Company strategy and market focus

• Emphasis on VOQUEZNA, a next-generation treatment for gastroesophageal reflux, targeting patients unresponsive to standard PPIs or H2 blockers.

• Strategic shift to focus sales efforts on gastroenterology prescribers, with 70% of sales calls now directed at this segment.

• Commercial organization consists of 300 sales reps, prioritizing efficiency and effectiveness in targeting high-need patients.

• Revenue guidance for 2026 is $320–345 million, with a goal to achieve operating profitability in Q3 and Q4 2026 and positive cash flow in 2027.

• Long-term growth strategy includes eventual expansion into primary care, driven by patient feedback and physician confidence.

Financial performance and capital structure

• VOQUEZNA generated $155 million in 2024 and $175 million in 2025, with strong year-over-year growth.

• Recent equity raise and debt restructuring have resulted in a sustainable, transparent, and cost-effective capital structure.

• Current term debt is $175 million at 9.85% interest, maturing in February 2029; cash on hand at the start of the year was about $190 million.

• Royalty financing remains unchanged at $275 million, with a 10% royalty and minimal cash flow requirements.

• Sufficient liquidity is expected to meet all obligations and support ongoing business investment.

Growth drivers and prescription trends

• Growth is driven by increasing prescription volume as physicians gain confidence in VOQUEZNA’s efficacy and access.

• Physicians typically start prescribing to severe cases, then broaden to more patients as positive outcomes are observed.

• Over 70% of prescriptions now originate from gastroenterology, with a natural evolution expected toward primary care adoption.

• Seasonality affects Q1 prescription volumes, but robust recovery is seen in March, mirroring previous years.

• IQVIA data primarily reflects covered scripts, which constitute the majority of revenue, though some under-capture exists.